Vale Professor Richard Scolyer AO
All of us at Melanoma Institute Australia (MIA) and the wider melanoma community are mourning the loss of our esteemed colleague and friend, Professor Richard Scolyer AO.
UV exposure leading cause of preventable cancers for Australian men
A World Health Organisation global study published in the Nature Medicine journal showed that 2 in every 5 cancers could be prevented. It found that in Australia the leading risk factor for preventable cancers in men is exposure to UV radiation.
Adjuvant vs Neoadjuvant – Further evidence for pre-surgery immunotherapy
Results of the RELATIVITY-098 clinical trial published in Nature Medicine show the presence of tumour is directly related to the effectiveness of combination immunotherapy for high risk and advanced melanoma, providing more evidence that neoadjuvant immunotherapy is the new frontier in treatment for melanoma, and other cancers.
Beyond NADINA – The new wave of neoadjuvant clinical trials
MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
Global award for neoadjuvant immunotherapy
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
Breakthrough melanoma treatment listed on PBS
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
NHMRC grants for UNCUT and Automate Me clinical trials
Prestigious National Health and Medical Research Council (NHMRC) grants have been awarded for two clinical trials aiming to improve the accuracy of skin cancer diagnosis in Australia.
Minimising surgery and drug intervention
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
MIA awarded prestigious NHMRC grant
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
Roadmap for a National Targeted Skin Cancer Screening Program
Skin checks are an important tool in the early detection of skin cancers. MIA & others in the skin cancer community have advocated for a more systematic, targeted & equitable approach to skin cancer screening in Australia. As a result, the Australian Gov't has allocated $10m for development of a Roadmap for a National Targeted Skin Cancer Screening Program.